Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Isolated limb perfusion with melphalan, tumour necrosis factor-alpha and oncolytic vaccinia virus improves tumour targeting and prolongs survival in a rat model of advanced extremity sarcoma.

Pencavel TD, Wilkinson MJ, Mansfield DC, Khan AA, Seth R, Karapanagiotou EM, Roulstone V, Aguilar RJ, Chen NG, Szalay AA, Hayes AJ, Harrington KJ.

Int J Cancer. 2015 Feb 15;136(4):965-76. doi: 10.1002/ijc.29059. Epub 2014 Jul 22.

2.

Optimising measles virus-guided radiovirotherapy with external beam radiotherapy and specific checkpoint kinase 1 inhibition.

Touchefeu Y, Khan AA, Borst G, Zaidi SH, McLaughlin M, Roulstone V, Mansfield D, Kyula J, Pencavel T, Karapanagiotou EM, Clayton J, Federspiel MJ, Russell SJ, Garrett M, Collins I, Harrington KJ.

Radiother Oncol. 2013 Jul;108(1):24-31. doi: 10.1016/j.radonc.2013.05.036. Epub 2013 Jul 9.

PMID:
23849174
3.

Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in (V600D/E)BRAF mutant melanoma depends on JNK and TNF-α signaling.

Kyula JN, Khan AA, Mansfield D, Karapanagiotou EM, McLaughlin M, Roulstone V, Zaidi S, Pencavel T, Touchefeu Y, Seth R, Chen NG, Yu YA, Zhang Q, Melcher AA, Vile RG, Pandha HS, Ajaz M, Szalay AA, Harrington KJ.

Oncogene. 2014 Mar 27;33(13):1700-12. doi: 10.1038/onc.2013.112. Epub 2013 Apr 29.

4.

Oncolytic reovirus type 3 (Dearing) as a novel therapy in head and neck cancer.

Kyula JN, Roulstone V, Karapanagiotou EM, Melcher AA, Harrington KJ.

Expert Opin Biol Ther. 2012 Dec;12(12):1669-78. doi: 10.1517/14712598.2012.745507. Review. Erratum in: Expert Opin Biol Ther. 2013 Jan;13(1):147.

PMID:
23140488
5.

Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway.

Twigger K, Roulstone V, Kyula J, Karapanagiotou EM, Syrigos KN, Morgan R, White C, Bhide S, Nuovo G, Coffey M, Thompson B, Jebar A, Errington F, Melcher AA, Vile RG, Pandha HS, Harrington KJ.

BMC Cancer. 2012 Aug 24;12:368. doi: 10.1186/1471-2407-12-368.

6.

Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy.

Roulstone V, Twigger K, Zaidi S, Pencavel T, Kyula JN, White C, McLaughlin M, Seth R, Karapanagiotou EM, Mansfield D, Coffey M, Nuovo G, Vile RG, Pandha HS, Melcher AA, Harrington KJ.

Gene Ther. 2013 May;20(5):521-8. doi: 10.1038/gt.2012.68. Epub 2012 Aug 16.

7.

Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies.

Karapanagiotou EM, Roulstone V, Twigger K, Ball M, Tanay M, Nutting C, Newbold K, Gore ME, Larkin J, Syrigos KN, Coffey M, Thompson B, Mettinger K, Vile RG, Pandha HS, Hall GD, Melcher AA, Chester J, Harrington KJ.

Clin Cancer Res. 2012 Apr 1;18(7):2080-9. doi: 10.1158/1078-0432.CCR-11-2181. Epub 2012 Feb 7.

8.

The need for third-line treatment in non-small cell lung cancer: an overview of new options.

Syrigos KN, Saif MW, Karapanagiotou EM, Oikonomopoulos G, De Marinis F.

Anticancer Res. 2011 Feb;31(2):649-59. Review.

PMID:
21378351
9.

Facial hypertrichosis and trichomegaly developing in patients treated with the epidermal growth factor receptor inhibitor erlotinib.

Vergou T, Stratigos AJ, Karapanagiotou EM, Matekovits AE, Dilana KD, Tsimboukis S, Antoniou C, Chasapi V, Syrigos KN.

J Am Acad Dermatol. 2010 Aug;63(2):e56-8. doi: 10.1016/j.jaad.2009.11.589. No abstract available.

PMID:
20633793
10.

Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers.

Harrington KJ, Karapanagiotou EM, Roulstone V, Twigger KR, White CL, Vidal L, Beirne D, Prestwich R, Newbold K, Ahmed M, Thway K, Nutting CM, Coffey M, Harris D, Vile RG, Pandha HS, Debono JS, Melcher AA.

Clin Cancer Res. 2010 Jun 1;16(11):3067-77. doi: 10.1158/1078-0432.CCR-10-0054. Epub 2010 May 18.

11.

Metastin is not involved in metastatic potential of non-small cell lung cancer.

Karapanagiotou EM, Dilana KD, Gkiozos I, Gratsias I, Tsimpoukis S, Polyzos A, Syrigos KN.

Med Oncol. 2011 Jun;28(2):559-64. doi: 10.1007/s12032-010-9466-7. Epub 2010 Mar 6.

PMID:
20213218
12.

Targeted therapeutic approaches for hormone-refractory prostate cancer.

Stavridi F, Karapanagiotou EM, Syrigos KN.

Cancer Treat Rev. 2010 Apr;36(2):122-30. doi: 10.1016/j.ctrv.2009.06.001. Epub 2010 Jan 27. Review.

PMID:
20106600
13.

Carboplatin-pemetrexed adjuvant chemotherapy in resected non-small cell lung cancer (NSCLC): a phase II study.

Karapanagiotou EM, Boura PG, Papamichalis G, Konstantinou M, Sepsas E, Chamalakis G, Simsiris P, Gkiozos I, Syrigos KN.

Anticancer Res. 2009 Oct;29(10):4297-301.

14.

Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol.

Syrigou EI, Karapanagiotou EM, Alamara CV, Boura PG, Saif MW, Syrigos KN.

Clin Colorectal Cancer. 2009 Apr;8(2):106-9.

PMID:
19739272
15.

Gastrointestinal bleeding as initial presentation of melanoma of unknown primary origin: report of a case and review of the literature.

Kotteas EA, Adamopoulos A, Drogitis PD, Zalonis A, Giannopoulos KV, Karapanagiotou EM, Saif MW, Syrigos KN.

In Vivo. 2009 May-Jun;23(3):487-9. Review.

16.

The clinical significance of serum markers of bone turnover in NSCLC patients: surveillance, management and prognostic implications.

Terpos E, Kiagia M, Karapanagiotou EM, Charpidou A, Dilana KD, Nasothimiou E, Harrington KJ, Polyzos A, Syrigos KN.

Anticancer Res. 2009 May;29(5):1651-7.

17.

Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol.

Syrigou EI, Karapanagiotou EM, Alamara CV, Boura PG, Saif MW, Syrigos KN.

Clin Colorectal Cancer. 2009 Mar;8(2):106-9.

PMID:
19423504
18.

Serum bone turnover markers may be involved in the metastatic potential of lung cancer patients.

Karapanagiotou EM, Terpos E, Dilana KD, Alamara C, Gkiozos I, Polyzos A, Syrigos KN.

Med Oncol. 2010 Jun;27(2):332-8. doi: 10.1007/s12032-009-9214-z. Epub 2009 Apr 17.

PMID:
19373566
19.

Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management.

Tsimboukis S, Merikas I, Karapanagiotou EM, Saif MW, Syrigos KN.

Clin Lung Cancer. 2009 Mar;10(2):106-11. doi: 10.3816/CLC.2009.n.013. Review.

PMID:
19362953
20.

Therapy-induced toxicity of the lungs: an overview.

Charpidou AG, Gkiozos I, Tsimpoukis S, Apostolaki D, Dilana KD, Karapanagiotou EM, Syrigos KN.

Anticancer Res. 2009 Feb;29(2):631-9. Review.

21.

Increased serum levels of ghrelin at diagnosis mediate body weight loss in non-small cell lung cancer (NSCLC) patients.

Karapanagiotou EM, Polyzos A, Dilana KD, Gratsias I, Boura P, Gkiozos I, Syrigos KN.

Lung Cancer. 2009 Dec;66(3):393-8. doi: 10.1016/j.lungcan.2009.02.006. Epub 2009 Mar 17.

PMID:
19282046
22.

Heat shock protein inhibitors and vaccines as new agents in cancer treatment.

Karapanagiotou EM, Syrigos K, Saif MW.

Expert Opin Investig Drugs. 2009 Feb;18(2):161-74. doi: 10.1517/13543780802715792 . Review.

PMID:
19236263
23.

Head and neck cancer in the elderly: an overview on the treatment modalities.

Syrigos KN, Karachalios D, Karapanagiotou EM, Nutting CM, Manolopoulos L, Harrington KJ.

Cancer Treat Rev. 2009 May;35(3):237-45. doi: 10.1016/j.ctrv.2008.11.002. Epub 2008 Dec 18. Review.

PMID:
19100689
24.

The role of mTOR in the management of solid tumors: an overview.

Strimpakos AS, Karapanagiotou EM, Saif MW, Syrigos KN.

Cancer Treat Rev. 2009 Apr;35(2):148-59. doi: 10.1016/j.ctrv.2008.09.006. Epub 2008 Nov 14. Review.

PMID:
19013721
25.

Renal oncocytoma: a case report and short review of the literature.

Alamara C, Karapanagiotou EM, Tourkantonis I, Xyla V, Maurer CC, Lykourinas M, Pandha H, Syrigos KN.

Eur J Intern Med. 2008 Nov;19(7):e67-9. doi: 10.1016/j.ejim.2008.03.003. Epub 2008 Apr 28. Review. No abstract available.

PMID:
19013370
26.

Soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) detection in cancer patients: a prognostic marker for lung metastases from solid malignancies.

Karapanagiotou EM, Pelekanou E, Charpidou A, Tsaganos T, Anagnostou V, Plachouras D, Giamarellos-Bourboulis EJ, Syrigos KN.

Anticancer Res. 2008 Mar-Apr;28(2B):1411-5.

27.

The significance of leptin, adiponectin, and resistin serum levels in non-small cell lung cancer (NSCLC).

Karapanagiotou EM, Tsochatzis EA, Dilana KD, Tourkantonis I, Gratsias I, Syrigos KN.

Lung Cancer. 2008 Sep;61(3):391-7. doi: 10.1016/j.lungcan.2008.01.018. Epub 2008 Mar 14.

PMID:
18342391
28.

A phase II study of sequential docetaxel and gemcitabine followed by docetaxel and carboplatin as first-line therapy for non-small cell lung cancer.

Karapanagiotou EM, Charpidou A, Tzannou I, Dilana K, Kotteas E, Tourkantonis I, Kosmas E, Provata A, Syrigos K.

Med Oncol. 2008;25(3):303-8. doi: 10.1007/s12032-007-9036-9. Epub 2008 Jan 17.

PMID:
18204976
29.

The use of radiolabeled somatostatin analog scintigraphy in the staging of small cell lung cancer patients.

Tzannou IA, Karapanagiotou EM, Charpidou A, Dilana K, Alamara C, Christakopoulou I, Georgiou E, Syrigos KN.

Am J Clin Oncol. 2007 Oct;30(5):503-6.

PMID:
17921711

Supplemental Content

Loading ...
Support Center